Skip to content
Study details
Enrolling now

Cryocompression With or Without Cilostazol for Paclitaxel-Induced Neuropathy

Emory University
NCT IDNCT06492070ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

70

Study length

about 3.4 years

Ages

18+

Sex

Female only

Locations

3 sites in GA

What this study is about

This trial is testing whether cryocompression therapy, alone or with cilostazol, can help prevent peripheral neuropathy caused by paclitaxel in women with gynecological cancers. Peripheral neuropathy is a common side effect of paclitaxel, which stops cancer cells from growing and dividing. Cryocompression combines compression garments with cooling to improve blood flow.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Best Practice
  • 2.Quality-of-Life Assessment
  • 3.Take Cilostazol
  • +2 more

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
OralInjection / IV

How treatment is administered

Treatment Assignment
Randomized (Open Label)

You are randomly assigned, but you will know your treatment.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

cilostazol, paclitaxel (Taxane chemotherapy; stabilizes microtubules)

Drug routes

oral (Oral Tablet), injection, intravenous

Endpoints

Secondary: Rate of grade 3 adverse events

Body systems

Oncology